ArticleRevista espanola de salud publica2025
[Validity of case definitions for Severe Acute Respiratory Infection based on ICD-10 codes in four autonomous communities (Spain, 2021-2023)].
Article in Revista espanola de salud publica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surveillance of severe acute respiratory infections associated with SARS-CoV-2, influenza virus and RSV using ICD-10 codes: a case definition accuracy study across five European countries, 2021 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveICD-10 diagnostic codes could be useful for automated surveillance of Severe Acute Respiratory Infection (SARI). This study analyzed the validity of different SARI case definitions (CD) based on ICD-10 codes at hospital discharge in Catalonia, the Valencian Community, Galicia and the Basque Country between weeks 21/2021 and 39/2023.
methodsPatients with respiratory system codes (J00 to J99, R06, U07) and with a laboratory test performed were included, with the gold standard being positivity to the corresponding pathogen. The validity of all possible combinations of ICD-10 codes was estimated, prioritizing the CDs according to the average sensitivity (Se) and specificity (Sp). Validity was estimated by age groups, but expert criteria were used to seek the optimal CD, unique for each pathogen, balancing validity and simplicity.
resultsThe CD selected for influenza for any age included the specific codes J09.X, J10.0, J10.1, J10.2, J10.8 and J11 (Se=95.4; Sp=99.7), and for SARS-CoV-2, codes U07.1 and J12.8 (Se=95.9; Sp=98.3). For RSV, validity was lower, with significant heterogeneity by age and inclusion of non-specific codes. The optimal CD included codes J06, J12.1, J13, J20.5, J21.0 and J45 (Se=63.9; Sp=88.4), recommending adding J98 for adults and when it is important to maximize Se (Se=88.9; Sp=65.3). The overall CD for the three viruses was consistent with the specific CDs.
conclusionsThe ICD-10 codes provides great validity in identifying influenza and SARS-CoV-2 hospitalizations, but shows poorer performance and greater age-group variability for RSV.
Indexed as
Identifiers
40503697PMC12160418What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.